The presentation is accessible on the Scientific Publications section of the Kailera website.

In preclinical studies, Rivus evaluated RV201 (ANT activator, investigational oral small molecule) as a single agent and in combination with semaglutide. Data demonstrated RV201 drives fat-selective, ...

Since 2019, the MRF has committed over $17 million to support 53 studies across 36 institutions, creating the world’s largest philanthropic portfolio dedicated solely to misophonia research. With each ...

These studies were completed as part of the Omada Insights Lab ANSWERS (ANalyzing Success of WEight medication with Real-world evidence and Stats) Initiative, which examines and shares real-world data ...

NEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...

With this growing body of evidence, Artelo continues to expand its leadership in the FABP inhibitor space. The Company maintains a portfolio of selective, dual, and pan inhibitors targeting FABP3, ...

CINCINNATI, Ohio, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Chemed Corporation (NYSE: CHE) today announced that it will deliver a presentation at the UBS 2025 Global Healthcare Conference on Tuesday, November ...

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association’s Sessions 2025 in New ...

Mr. Bagai will share an update on RenovoRx’s commercialization progress, driven by strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new ...

With new and elevated leaders, InStride is poised to scale its care model while maintaining its differentiated specialty care. BOSTON, Nov. 04, 2025 (GLOBE NEWSWIRE) -- InStride H ...

Summary: Preclinical and clinical data support the continued development of ARD-201 to attenuate weight gain, promote weight loss, and help maintain weight after the discontinuation of glucagon-like ...

BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced ...